Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Muenzer

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomasS G Chi, R W deVere White, J T Muenzer, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 5, 2002
BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agentsX B Shi, P H Gumerlock, J T Muenzer, et al.
Cancer|December 24, 1997
p53-independent response of a human breast carcinoma xenograft to radioimmunotherapyM D Winthrop, S J DeNardo, J T Muenzer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomasS G Chi, R W deVere White, J T Muenzer, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 5, 2002
BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agentsX B Shi, P H Gumerlock, J T Muenzer, et al.
Cancer|December 24, 1997
p53-independent response of a human breast carcinoma xenograft to radioimmunotherapyM D Winthrop, S J DeNardo, J T Muenzer, et al.
Pageof 1